Gametocytocidal and Transmission-blocking Efficacy of ASAQ and ALAQ With or Without PQ in Mali
Status:
Not yet recruiting
Trial end date:
2023-01-13
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the gametocytocidal and transmission reducing
activity of artesunate-amodiaquine (ASAQ) and artemether-lumefrantrine-amodiaquine (ALAQ)
with and without a single dose of 0.25mg/kg primaquine (PQ). Outcome measures will include
infectivity to mosquitoes at 2, 7 and 14 days after treatment, gametocyte density throughout
follow-up, and safety measures including haemoglobin density and the frequency of adverse
events.
Phase:
Phase 2
Details
Lead Sponsor:
London School of Hygiene and Tropical Medicine
Treatments:
Amodiaquine Amodiaquine, artesunate drug combination Artemether Artemether, Lumefantrine Drug Combination Artesunate Lumefantrine Primaquine